Insider Transactions in Q4 2022 at Cytokinetics Inc (CYTK)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 21
2022
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-2.4%
|
$430,000
$43.92 P/Share
|
|
Dec 21
2022
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.35%
|
$90,000
$9.65 P/Share
|
|
Dec 08
2022
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
4,000
-2.43%
|
$144,000
$36.28 P/Share
|
|
Dec 05
2022
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-2.4%
|
$390,000
$39.3 P/Share
|
|
Dec 05
2022
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.35%
|
$90,000
$9.65 P/Share
|
|
Nov 21
2022
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-2.4%
|
$400,000
$40.89 P/Share
|
|
Nov 21
2022
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.35%
|
$90,000
$9.65 P/Share
|
|
Nov 14
2022
|
Robert Wong VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,100
-6.43%
|
$84,000
$40.68 P/Share
|
|
Nov 10
2022
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
4,000
-2.38%
|
$152,000
$38.04 P/Share
|
|
Nov 02
2022
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-1.21%
|
$420,000
$42.17 P/Share
|
|
Nov 02
2022
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+1.18%
|
$80,000
$8.81 P/Share
|
|
Oct 19
2022
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-2.4%
|
$470,000
$47.86 P/Share
|
|
Oct 19
2022
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.35%
|
$70,000
$7.96 P/Share
|
|
Oct 13
2022
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
21,513
-11.33%
|
$1,011,111
$47.28 P/Share
|
|
Oct 13
2022
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
21,513
+10.18%
|
$193,617
$9.65 P/Share
|
|
Oct 03
2022
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
110
+0.96%
|
$5,610
$51.11 P/Share
|
|
Oct 03
2022
|
Wendall Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
110
+0.89%
|
$5,610
$51.11 P/Share
|
|
Oct 03
2022
|
Sandford D Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
110
+0.89%
|
$5,610
$51.11 P/Share
|
|
Oct 03
2022
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
220
+1.69%
|
$11,220
$51.11 P/Share
|
|
Oct 03
2022
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
391
+1.57%
|
$19,941
$51.11 P/Share
|
|
Oct 03
2022
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-2.4%
|
$500,000
$50.4 P/Share
|
|
Oct 03
2022
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.35%
|
$70,000
$7.96 P/Share
|
|
Oct 03
2022
|
Muna Bhanji Director |
BUY
Grant, award, or other acquisition
|
Direct |
220
+1.96%
|
$11,220
$51.11 P/Share
|